Category: 152265-57-1

Reference of 152265-57-1, Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In some cases, the catalyzed mechanism may include additional steps.In a article, 152265-57-1, molcular formula is C8H5BrN2O, introducing its new discovery.

CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS

This invention provides compounds defined by Formula I Z-L-R1-Q-D-(V1)m-R2 I or a pharmaceutically acceptable salt thereof, wherein Z, L, R1, Q, D, V1, m, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.

The proportionality constant is the rate constant for the particular unimolecular reaction. the reaction rate is directly proportional to the concentration of the reactant. I hope my blog about 152265-57-1 is helpful to your research. Reference of 152265-57-1

Reference£º
Phthalazine – Wikipedia,
Phthalazine | C8H6N707 – PubChem

152265-57-1, Name is 7-Bromophthalazin-1(2H)-one, belongs to phthalazine compound, is a common compound. SDS of cas: 152265-57-1In an article, once mentioned the new application about 152265-57-1.

Rhodium(III)-Catalyzed C-H Functionalization of 1-(2H)-Phthalazinones at C8

The rhodium(III) catalyst tris(acetonitrile)pentamethylcyclopentadienylrhodium(III) hexafluoroantimonate ([Cp*Rh(MeCN)3](SbF6)2) reacts with 1-(2H)-phthalazinones to promote a C-H functionalization event at C8. Preparation of a set of compounds arising from oxidative alkenylation with olefins, hydroarylation with alkynes, and iodination with N-iodosuccinimide is reported here. Oxidative alkenylation proceeds in very good yield, and the scope and limitations of the hydroarylation and halogenation reactions are discussed. Notably, this strategy enables rapid preparation of C8-substituted phthalazinones without requiring phthalazinone ring synthesis starting from a prefunctionalized arene.

Do you like my blog? If you like, you can also browse other articles about this kind. Thanks for taking the time to read the blog about 152265-57-1

Reference£º
Phthalazine – Wikipedia,
Phthalazine | C8H6N712 – PubChem

One of the major reasons for studying chemical kinetics is to use measurements of the macroscopic properties of a system, Recommanded Product: 7-Bromophthalazin-1(2H)-one, such as the rate of change in the concentration of reactants or products with time.In a article, mentioned the application of 152265-57-1, Name is 7-Bromophthalazin-1(2H)-one, molecular formula is C8H5BrN2O

FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Q, R1, X1, X2, Y and R2 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

One of the oldest and most widely used commercial enzyme inhibitors is aspirin, Recommanded Product: 7-Bromophthalazin-1(2H)-one, which selectively inhibits one of the enzymes involved in the synthesis of molecules that trigger inflammation. you can also check out more blogs about 152265-57-1

Reference£º
Phthalazine – Wikipedia,
Phthalazine | C8H6N705 – PubChem

152265-57-1, Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In a patent, 152265-57-1, molecular formula is C8H5BrN2O, introducing its new discovery.

CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF

Disclosed are a condensed ring derivative, and a preparation method, an intermediate, a pharmaceutical composition and a use thereof. The condensed ring derivative of the present invention has a significant inhibitive effect on URAT1, which can effectively alleviate or treat hyperuricemia and other related diseases.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.152265-57-1, you can also check out more blogs about152265-57-1

Reference£º
Phthalazine – Wikipedia,
Phthalazine | C8H6N710 – PubChem

Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent£¬Which mentioned a new discovery about 152265-57-1, molcular formula is C8H5BrN2O, introducing its new discovery. , 152265-57-1

BENZOXAZINONE DERIVATIVES AND ANALOGUES THEREOF AS MODULATORS OF TNF ACTIVITY

A series of substituted 3,4-dihydro-2H-.1,4-benzoxazin-3-one derivatives, and analogues thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neuradegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Because enzymes can increase reaction rates by enormous factors and tend to be very specific, 152265-57-1, typically producing only a single product in quantitative yield, they are the focus of active research.you can also check out more blogs about 152265-57-1

Reference£º
Phthalazine – Wikipedia,
Phthalazine | C8H6N704 – PubChem

152265-57-1, We know that the rate of many reactions can be accelerated by catalysts. A catalyst speeds up the rate of a reaction by lowering the activation energy; in addition, the catalyst is regenerated in the process. 7-Bromophthalazin-1(2H)-one, cas is 152265-57-1,the phthalazine compound, below Introduce a new synthetic route.

A mixture of 7-bromo-l,2-dihydrophthalazin-l-one (4.1 g, 18.22 mmol) and bis(pinacolato)diboron (12.95 g, 51.01 mmol) was dissolved in 1,4-dioxane (150 mL) under nitrogen. Potassium acetate (5.36 g, 54.66 mmol) was added, and the reaction mixture was degassed with N2 for 5 minutes. Pd(dppf)Cl2 (0.74 g, 0.91 mmol) was added and the mixture was heated at 110C for 1.5 h, then cooled and diluted with DCM. The solids were removed by filtration through celite. The residue was washed with DCM and the combined organic phases were concentrated in vacuo. The resulting solid was triturated in heptane (30 mL) and diethyl ether (15 mL). The solid was further triturated with heptane (30 mL) and diethyl ether (15 mL), then the precipitate was collected by filtration, to give the title compound (5.1 g, 81%). deltaEta (250 MHz, DMSO-d6) 12.68 (s, 1H), 8.50 (s, 1H), 8.37 (s, 1H), 8.10 (dd, J7.8, 1.1 Hz, 1H), 7.88 (d, J7.8 Hz, 1H), 1.30 (s, 12H). Method B: HPLC-MS MH+ mlz 273, RT 1.78 minutes (97%)

Any one of these steps may be slow and thus may serve as the rate determining step. In general, however, in the presence of the catalyst, the overall rate of the reaction is faster than it would be if the reactants were in the gas or liquid phase., 152265-57-1

Reference£º
Patent; UCB BIOPHARMA SPRL; BRACE, Gareth Neil; CHOVATIA, Prafulkumar Tulshibhai; FOULKES, Gregory; JOHNSON, James Andrew; JONES, Severine Danielle; KROEPLIEN, Boris; LECOMTE, Fabien Claude; LOKE, Pui Leng; LOWE, Martin Alexander; MANDAL, Ajay; NORMAN, Timothy John; PALMER, Christopher Francis; PEREZ-FUERTES, Yolanda; PORTER, John Robert; SMYTH, Donald; TRANI, Giancarlo; UDDIN, Muhammed; ZHU, Zhaoning; (207 pag.)WO2016/198400; (2016); A1;,
Phthalazine – Wikipedia
Phthalazine | C8H6N2 – PubChem

152265-57-1, In the next few decades, the world population will flourish. As the population grows rapidly and people all over the world use more and more resources, all industries must consider their environmental impact. 7-Bromophthalazin-1(2H)-one, cas is 152265-57-1,the phthalazine compound, it is a common compound, a new synthetic route is introduced below.

Example 807-(4-(trifluoromethoxy)phenyl)phthalazin-1(2H)-one (Compound III-1) A mixture of 7-bromophthalazinone (1.09 g, 4.84 mmol), 4-trifluoromethoxyphenyl boronic acid (1.20 g, 5.81 mmol), dppf(Pd)Cl2 (177 mg, 0.242 mmol), potassium carbonate (1.34 g, 9.68 mmol) in degassed toluene (4 mL), degassed water (2 mL) and degassed isopropanol (2 mL) was heated at 90 C. for 12 hours. The layers were separated, the organic layer was concentrated and the residue was purified by trituration with hexanes/ethyl acetate to provide 7-(4-(trifluoromethoxy)phenyl)phthalazin-1(2H)-one as a white powder. C15H9F3N2O2. 307.2 (M+1).

Chemical properties determine the actual use. Each compound has specific chemical properties and uses. We look forward to more synthetic routes in the future to expand reaction routes of 7-Bromophthalazin-1(2H)-one, 152265-57-1

Reference£º
Patent; Gilead Sciences, Inc.; US2012/289493; (2012); A1;,
Phthalazine – Wikipedia
Phthalazine | C8H6N2 – PubChem

As a common heterocyclic compound, it belongs to phthalazine compound, name is 7-Bromophthalazin-1(2H)-one, and cas is 152265-57-1, its synthesis route is as follows.

10198] 7-l3romo- 1 -chlorophthalazine (9a) In a flame dried25 mE round bottom flask was added 7-bromophthalazin-1 (2H)-one (205 mg, 0.91 mmol), anhydrous acetonitrile (9 mE), and phosphorus oxychloride (0.3 mE, 3.22 mmol). The mixture was refluxed for 2 hours, then cooled to 00 C., diluted with dichloromethane (20 mE), and quenched with a drop- wise addition of sat. aq. NaHCO3 (20 mE). The biphasic mixture was stirred vigorously and allowed to warm to room temperature. Afier 1 hour the layers were separated and the aqueous was extractedwith dichioromethane (2×30 mE). The combined organic layers were washed with sat. aq. NaHCO3 (25 mE), washed with brine (20 mE), dried over Na2SO4, and concentrated to yield 9a as an orange solid in 91% yield. ?HNMR (500 MHz, CDC13) oe 9.45 (s, 1H), 8.49-8.5 1 (m, 1H), 8.10 (dd, J=8.8, 2.0 Hz, 1H), 7.91 (d, J=8.8 Hz, 1H). ECMS found 242.9 [M+H].

152265-57-1, In the field of chemistry, the synthetic routes of compounds are constantly being developed and updated. I will also mention this compound in other articles.,152265-57-1 ,7-Bromophthalazin-1(2H)-one, other downstream synthetic routes, hurry up and to see

Reference£º
Patent; Northeastern University; POLLASTRI, Michael P.; MEHTA, Naimee; DEVINE, William; WOODRING, Jennifer; SWAMINATHAN, Uma; US2015/259331; (2015); A1;,
Phthalazine – Wikipedia
Phthalazine | C8H6N2 – PubChem

As a common heterocyclic compound, it belongs to phthalazine compound, name is 7-Bromophthalazin-1(2H)-one, and cas is 152265-57-1, its synthesis route is as follows.

A mixture of compound 50-d (600mg, 2.67mmol) and POCl3 (8mL) was heated to reflux for 1.5h, cooled toroom temperature and concentrated under reduced pressure. The residue was dissolved in DCM (40mL), washed inturn with saturated sodium bicarbonate (40mL) and saturated brine (10mL), dried over anhydrous sodium sulfate, filteredand concentrated under reduced pressure. The residue was purified by silica column chromatography (PE:EA = 3:1) togive compound 50-c (500mg, yield 75%). LC-MS (ESI): m/z = 243 [M+H]+.

152265-57-1, In the field of chemistry, the synthetic routes of compounds are constantly being developed and updated. I will also mention this compound in other articles.,152265-57-1 ,7-Bromophthalazin-1(2H)-one, other downstream synthetic routes, hurry up and to see

Reference£º
Patent; Shanghai Yingli Pharmaceutical Co. Ltd.; XU, Zusheng; ZHANG, Nong; SUN, Qingrui; WU, Tianzhi; (104 pag.)EP3275867; (2018); A1;,
Phthalazine – Wikipedia
Phthalazine | C8H6N2 – PubChem

As a common heterocyclic compound, it belongs to phthalazine compound, name is 7-Bromophthalazin-1(2H)-one, and cas is 152265-57-1, its synthesis route is as follows.

A mixture of 7-bromo-l,2-dihydrophthalazin-l-one (4.1 g, 18.22 mmol) and bis(pinacolato)diboron (12.95 g, 51.01 mmol) was dissolved in 1,4-dioxane (150 mL) under nitrogen. Potassium acetate (5.36 g, 54.66 mmol) was added, and the reaction mixture was degassed with N2 for 5 minutes. Pd(dppf)Cl2 (0.74 g, 0.91 mmol) was added and the mixture was heated at 110C for 1.5 h, then cooled and diluted with DCM. The solids were removed by filtration through celite. The residue was washed with DCM and the combined organic phases were concentrated in vacuo. The resulting solid was triturated in heptane (30 mL) and diethyl ether (15 mL). The solid was further triturated with heptane (30 mL) and diethyl ether (15 mL), then the precipitate was collected by filtration, to give the title compound (5.1 g, 81%). deltaEta (250 MHz, DMSO-d6) 12.68 (s, 1H), 8.50 (s, 1H), 8.37 (s, 1H), 8.10 (dd, J7.8, 1.1 Hz, 1H), 7.88 (d, J7.8 Hz, 1H), 1.30 (s, 12H). Method B: HPLC-MS MH+ mlz 273, RT 1.78 minutes (97%)

152265-57-1, In the field of chemistry, the synthetic routes of compounds are constantly being developed and updated. I will also mention this compound in other articles.,152265-57-1 ,7-Bromophthalazin-1(2H)-one, other downstream synthetic routes, hurry up and to see

Reference£º
Patent; UCB BIOPHARMA SPRL; BRACE, Gareth Neil; CHOVATIA, Prafulkumar Tulshibhai; FOULKES, Gregory; JOHNSON, James Andrew; JONES, Severine Danielle; KROEPLIEN, Boris; LECOMTE, Fabien Claude; LOKE, Pui Leng; LOWE, Martin Alexander; MANDAL, Ajay; NORMAN, Timothy John; PALMER, Christopher Francis; PEREZ-FUERTES, Yolanda; PORTER, John Robert; SMYTH, Donald; TRANI, Giancarlo; UDDIN, Muhammed; ZHU, Zhaoning; (207 pag.)WO2016/198400; (2016); A1;,
Phthalazine – Wikipedia
Phthalazine | C8H6N2 – PubChem